Antibe Therapeutics Announces the Formation of Its Clinical Advisory Board
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE) is pleased to announce the formation of its Clinical Advisory Board with the appointment of three distinguished, internationally recognized gastroenterologists. The three appointees are: Dr. Francis Chan, Professor of Medicine at The Chinese University of Hong Kong; Dr. Angel Lanas, Professor of Medicine, University of Zaragoza (Spain); and Dr. James Scheiman, Professor of Internal Medicine at the University of Michigan.
Antibe’s Chief Science Officer, Dr. John Wallace, remarked, “We are exceptionally pleased and honoured to have these three globally recognized clinical investigators on our Clinical Advisory Board. Drs. Chan, Lanas, and Scheiman have designed and been the chief investigators of large clinical trials in the anti-inflammatory space including those that resulted in the marketing approval of Celebrex, now one of the most widely prescribed arthritis treatment medications.”
Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammatory conditions such as arthritis, yet they are associated with serious and potentially life-threatening side effects including gastrointestinal ulceration and bleeding in some patients. Antibe’s lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, the most prescribed NSAID in North America. In pre-clinical testing, ATB-346 exhibited comparable anti-inflammatory activity to naproxen, but with markedly reduced adverse gastrointestinal effects. It is presently being evaluated in a phase I human clinical trial. The Clinical Advisory Board will play a major role in designing Antibe’s future clinical development program, aimed at demonstrating the efficacy and improved safety of ATB-346 in humans.
The Corporation is also pleased to announce that Jeremy Grushcow, Ph.D., J.D. has moved to a full-time position as EVP, Strategic Development. In connection with his full time appointment, Dr. Grushcow has been granted options to purchase a total of 150,000 common shares of Antibe pursuant to the Corporation’s stock option plan. Each option bears an exercise price of $0.59, being the closing price of Antibe shares on July 16, 2014, and an expiry date July 16, 2024. Twenty-five percent of the options vest on the grant date and 1/36th of the remaining options vest in each of the subsequent 36 months.
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. develops safer medicines for pain and inflammation. These medicines are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body, to regulate a range of fundamental cellular processes. The company's drug design approach involves chemically linking an existing off-patent drug to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation or pain, this approach can efficiently produce improved versions of existing drugs.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.